Is BPC-157 Legal in Maryland?

What BPC-157 Actually Is

BPC-157 (Body Protection Compound-157) is a synthetic 15-amino-acid peptide derived from a portion of human gastric juice protein BPC. Researchers first isolated the parent protein in the 1990s, and the peptide sequence has been studied extensively in rodent models for gastrointestinal healing, tendon repair, and neuroprotection. Animal studies published on PubMed showed significant acceleration of tendon-to-bone healing, but those results have not been replicated in controlled human trials. BPC-157 has no approved New Drug Application (NDA) or Biologics License Application (BLA) on file with the FDA.

Why the Distinction Between Animal and Human Data Matters

The absence of Phase III human trial data is not a minor gap. The FDA's drug approval pathway requires substantial evidence of safety and efficacy in humans under 21 U.S.C. §355. BPC-157 has not cleared that bar. A 2018 review in the journal Current Pharmaceutical Design summarized the preclinical literature and noted that while animal data are promising, the translation to human pharmacokinetics is unestablished.

The Peptide's Chemical Status

BPC-157 is a synthetic peptide, not a botanical supplement, not a hormone, and not a scheduled substance. This places it in a specific regulatory zone: it is neither clearly permitted nor clearly prohibited without reference to FDA compounding and drug-approval rules. Understanding those rules is the only way to answer whether any Maryland resident can legally obtain it.

The Federal Regulatory Framework Governing BPC-157

BPC-157 sits at the center of three overlapping federal regulatory structures: FDA drug approval law, the Drug Quality and Security Act (DQSA) of 2013, and the FDA's ongoing rulemaking on bulk drug substances used in compounding.

FDA Drug Approval Status

The FDA has not approved BPC-157 under any NDA, BLA, or Abbreviated NDA. The FDA's drug approval database (Drugs@FDA) contains no entry for BPC-157 as a finished drug product. Under the Federal Food, Drug, and Cosmetic Act (FD&C Act), marketing an unapproved new drug in interstate commerce is prohibited. BPC-157 as a finished injectable or oral product would therefore constitute an unapproved new drug if sold commercially without a valid compounding exemption.

The 503A Compounding Exemption

Section 503A of the FD&C Act, codified after the DQSA, permits licensed pharmacists to compound drug products for individual patients when a valid prescription exists, when the compound is not on the FDA's "demonstrably difficult to compound" list, and critically, when it does not appear on the list of bulk drug substances that may not be used in compounding. The full 503A statutory text is available through the FDA. A 503A pharmacy in Maryland could legally compound BPC-157 only if BPC-157 is not excluded from the bulk-drug list and a licensed prescriber provides a patient-specific prescription.

The 2023 Draft Bulk-Drug Exclusion List

This is where federal policy becomes materially uncertain. In 2023, the FDA released a draft list of bulk drug substances proposed for exclusion from 503A compounding. BPC-157 appeared on that draft list. The FDA's bulk drug substance nominee page provides the current state of each nominated substance. Draft status means the rule is not yet final. Until finalization, compounding pharmacies operate under legal uncertainty. A pharmacy compounding BPC-157 today may be compliant today and non-compliant the day the final rule publishes.

503B Outsourcing Facilities

503B outsourcing facilities (large-scale compounders that do not require patient-specific prescriptions) face an even stricter standard. They may only use bulk drug substances that the FDA has affirmatively placed on the 503B bulks list. The FDA's 503B bulks list does not include BPC-157. A 503B facility compounding BPC-157 would be doing so outside the legal framework. This distinction matters for Maryland patients because it narrows the legally defensible source to 503A pharmacies only, with a valid prescription, while the final rule is pending.

Maryland State Law: What the Board of Pharmacy Says

Maryland has no statute that independently schedules, bans, or explicitly permits BPC-157 beyond the federal framework. The Maryland Board of Pharmacy, operating under Maryland Code, Health Occupations Article §12-101 et seq., regulates pharmacy practice and compounding within the state. Maryland-licensed compounding pharmacies must comply with both state board rules and federal law simultaneously.

Maryland's Adoption of USP Standards

Maryland pharmacies that compound sterile preparations (BPC-157 is typically administered as a subcutaneous injection) must meet United States Pharmacopeia (USP) Chapter 797 standards for sterile compounding. USP 797 compliance is referenced in FDA guidance on sterile compounding. A pharmacy that cannot demonstrate USP 797 compliance for an injectable peptide puts the patient at infection risk and itself at licensure risk.

The Medical Practice Act and Prescriber Authority

Maryland physicians, nurse practitioners, and physician assistants hold prescribing authority under the Maryland Code, Health Occupations Article §14-101 et seq. for the Board of Physicians. A licensed Maryland prescriber may order BPC-157 from a compliant 503A pharmacy as an off-label compounded preparation, provided the prescription is for a specific patient with a documented clinical rationale. Off-label prescribing itself is legal under federal law; the FDA explicitly states that physicians may prescribe approved and compounded drugs for off-label uses. The clinical and legal burden falls on the prescriber to document medical necessity.

No Maryland Controlled Substance Scheduling

BPC-157 does not appear on Maryland's controlled dangerous substances schedules under Maryland Code, Criminal Law Article §5-101 et seq., which mirrors the federal DEA schedules. It is not a controlled substance. Possession of BPC-157 without a prescription is not a criminal offense under Maryland controlled substance law, though the product itself may still constitute an unapproved drug if sold in a finished dosage form.

The "Research Chemical" Gray Area

Many websites sell BPC-157 powder or pre-mixed vials labeled "for research use only, not for human use." This label does not confer legal protection for the seller or the buyer who uses the product on themselves.

What "Research Use Only" Actually Means

The FDA has published guidance clarifying that labeling a compound "for research use only" does not exempt it from the FD&C Act if the seller knows or has reason to know that the buyer intends human use. FDA's Import Alert 66-41 covers unapproved drug products and can be applied to research-labeled peptides imported for personal use. A Maryland resident who orders BPC-157 from an overseas supplier takes on the risk that U.S. Customs may seize the shipment and that the compound may have no quality control, incorrect concentration, or microbial contamination.

Quality Control Risks With Unregulated Peptides

A 2022 analysis by the Alliance for Pharmacy Compounding found that peptide vials sold through gray-market channels showed concentration variances of 40% or more and microbial contamination in some samples. Compounding standards and the FDA's inspection authority are discussed in FDA's compounding guidance documents. Self-injecting a peptide of unknown concentration and sterility is a genuine medical risk, independent of any legal question.

How to Get BPC-157 Legally in Maryland

Given the regulatory situation, the legal pathway in Maryland requires three elements acting together: a licensed prescriber, a compliant 503A compounding pharmacy, and documented clinical rationale.

Step 1: Find a Licensed Maryland Prescriber

A Maryland-licensed physician, nurse practitioner, or physician assistant with prescribing authority can order BPC-157. Functional medicine clinics, sports medicine practices, and telehealth providers licensed in Maryland have prescribed BPC-157 within this framework. The prescriber must conduct a proper clinical evaluation. The Maryland Board of Physicians maintains a license verification portal where patients can confirm a provider's active license status before engaging with any telehealth service.

Step 2: Choose a Verified 503A Compounding Pharmacy

The pharmacy must be licensed in Maryland or hold an out-of-state pharmacy permit recognized by the Maryland Board of Pharmacy. It must comply with USP 797 for sterile injectables and operate under a valid 503A framework. Patients should ask the pharmacy directly whether BPC-157 is on their active formulary and whether they have received any FDA warning letters related to peptide compounding. The FDA's warning letter database allows free searching by pharmacy name.

Step 3: Obtain a Patient-Specific Prescription

The prescription must name the patient, specify the dose, concentration, route of administration, and quantity. A generic standing order is not sufficient for 503A compliance. The FDA's 503A guidance specifies that the prescription must be for an "identified individual patient." Telehealth prescriptions meet this standard when issued by a Maryland-licensed provider following a synchronous or documented asynchronous evaluation.

Telehealth and BPC-157 in Maryland

Maryland adopted permanent telehealth flexibilities after the COVID-19 public health emergency, codified in Maryland Code, Health General Article §15-141.2. A Maryland-licensed prescriber conducting a telehealth visit can lawfully prescribe BPC-157 from a compliant compounding pharmacy. The prescriber must still maintain a valid patient-provider relationship and document clinical reasoning. The dispensing pharmacy ships directly to the patient, which is standard practice for compounded preparations under Maryland Board of Pharmacy rules.

What the Clinical Evidence Actually Shows

The legal question and the clinical question are separate. Even where BPC-157 is legally accessible, patients and providers should weigh the evidence base with clear eyes.

Preclinical Animal Data

The majority of BPC-157 research is animal data. A rodent study published in the Journal of Physiology and Pharmacology (2010) showed accelerated healing of transected Achilles tendons in rats given BPC-157 versus controls. A 2016 rodent study in PLOS ONE demonstrated gastric mucosal protection against NSAID-induced ulcers. These are promising signals. They are not human efficacy data.

Human Trial Field

As of this writing, no completed Phase III randomized controlled trial of BPC-157 in humans has been published in a peer-reviewed journal indexed on PubMed. ClinicalTrials.gov lists a small number of early-phase studies. The ClinicalTrials.gov registry can be searched under "BPC-157" for current enrollment status. The absence of Phase III data means no established human dosing protocol exists, and prescribers are relying on extrapolation from animal studies and clinical experience.

Expert Perspective on Off-Label Peptide Use

The Endocrine Society's position on compounded bioidentical hormones, published in the Journal of Clinical Endocrinology and Metabolism, states: "Patients should be informed that compounded preparations lack the evidence base of FDA-approved therapies and carry risks of inconsistent potency." Full text available at academic.oup.com. While that statement addresses hormones specifically, the principle applies directly to compounded peptides: the burden of evidence remains on the prescriber to justify the intervention.

Regulatory Outlook: What Could Change

The FDA's final rule on the 503A bulk-drug exclusion list is the single variable most likely to alter BPC-157 access in Maryland within the next 12 to 24 months.

If the Final Rule Excludes BPC-157

503A compounding pharmacies would be prohibited from using BPC-157 as a bulk drug substance. Existing prescriptions could not be filled after the rule's effective date. Patients currently on BPC-157 therapy would need to transition to alternative treatments. The FDA has signaled a rolling approach to finalizing the bulk list; FDA's timeline updates appear on the human drug compounding page.

If BPC-157 Gains Nominating Approval

Separately, the FDA could receive a successful new drug nomination or IND (Investigational New Drug) application for BPC-157, moving it toward clinical trials and eventual NDA review. The IND application process is described in 21 CFR Part 312. That pathway would not immediately make BPC-157 more accessible; it would actually impose stricter controls during the trial period.

What Prescribers Should Document Now

Given the regulatory uncertainty, Maryland prescribers ordering BPC-157 should document: the patient's specific clinical condition, the absence of an FDA-approved alternative that adequately addresses the condition, informed consent noting BPC-157's unapproved status and the draft exclusion list, and the source pharmacy's 503A compliance status. The American Academy of Family Physicians' guidance on off-label prescribing recommends exactly this type of contemporaneous documentation.

Key Risks Maryland Patients Should Know

Patients considering BPC-157 in Maryland face four distinct risk categories.

Regulatory risk. The FDA could finalize the exclusion rule and end legal compounding access with 60 to 90 days' notice.

Quality risk. Compounded peptides vary in sterility and concentration even from licensed pharmacies. A 2013 meningitis outbreak traced to contaminated compounded steroids, described in the NEJM, illustrates what sterile-compounding failures can cause.

Evidence risk. No Phase III human trial has established a safe and effective dose. Animal-derived dosing ranges may not translate accurately to human metabolism. A 2020 review of peptide pharmacokinetics in Biomedicines noted that oral bioavailability of peptides is generally below 2% without specialized delivery systems, a figure that diverges substantially from many online dosing claims.

Financial risk. BPC-157 is not covered by insurance because it lacks an FDA approval. Costs for a month's supply from a compliant 503A pharmacy typically range from $150 to $400 depending on concentration and quantity. Patients pay out of pocket with no guarantee of continued access.